95 related articles for article (PubMed ID: 5866829)
1. [Secretion of mesobilifuscine in diseases of the liver].
Netousek M; Moravec M
Acta Hepatosplenol; 1965; 12(5):279-84. PubMed ID: 5866829
[No Abstract] [Full Text] [Related]
2. [Metabolism of bile pigments and hepatic chromo-secretion in relation to clinical diagnosis of icterus].
Jirsa M; Hykes P
Cas Lek Cesk; 1972; 111(39):902-4. PubMed ID: 5078494
[No Abstract] [Full Text] [Related]
3. [Activity of granulocytic alkaline phosphatase in parenchymal liver diseases of varied etiology].
Wichrzycka E; Pawelski S
Pol Tyg Lek; 1966 Jan; 21(3):86-8. PubMed ID: 5907711
[No Abstract] [Full Text] [Related]
4. [Prescription of drugs in liver diseases].
Held H
Internist (Berl); 1980 Dec; 21(12):724-34. PubMed ID: 7009474
[No Abstract] [Full Text] [Related]
5. [Alcohol catabolism in liver diseases].
Lelbach WK
Dtsch Med Wochenschr; 1969 May; 94(21):1136-7. PubMed ID: 5769159
[No Abstract] [Full Text] [Related]
6. Clinical aspects of bile acid metabolism in liver diseases.
Iwamura K
Tokai J Exp Clin Med; 1982 Jan; 7(1):7-29. PubMed ID: 6281949
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma tyrosine concentrations in patients with cirrhosis and fulminant hepatic failure associated with increased plasma tyrosine flux and reduced hepatic oxidation capacity.
O'Keefe SJ; Abraham R; El-Zayadi A; Marshall W; Davis M; Williams R
Gastroenterology; 1981 Dec; 81(6):1017-24. PubMed ID: 7286580
[No Abstract] [Full Text] [Related]
8. [Angiotensin-converting enzyme inhibitors in liver function disorders?].
Bönner G
Dtsch Med Wochenschr; 1996 Feb; 121(8):254. PubMed ID: 8815027
[No Abstract] [Full Text] [Related]
9. [Aspects of cortisol metabolism in liver diseases].
Della Casa L; Boni M
Endocrinol Sci Cost; 1967 Nov; 29(5):344-53. PubMed ID: 5616116
[No Abstract] [Full Text] [Related]
10. [On the competitive manifestations in liver chromosecretion].
Hoenig V; Kucerová L
Cas Lek Cesk; 1968 Apr; 107(17):504-6. PubMed ID: 5664830
[No Abstract] [Full Text] [Related]
11. [Glycoregulation and liver diseases].
Guillon J; Charbonnel B; Le Bodic L; Chupin M; Ozanne P; Veyrac MJ
Journ Annu Diabetol Hotel Dieu; 1980 May; ():181-95. PubMed ID: 6995669
[No Abstract] [Full Text] [Related]
12. Hepatic fibrosis.
Rojkind M; Kershenobich D
Clin Gastroenterol; 1981 Sep; 10(3):737-54. PubMed ID: 6274551
[No Abstract] [Full Text] [Related]
13. [Protein-copper complex in primary biliary cirrhosis and other chronic diffuse diseases of the liver].
Loginov AS; Aruin LI; Shepeleva SD
Arkh Patol; 1980; 42(4):50-5. PubMed ID: 7396755
[TBL] [Abstract][Full Text] [Related]
14. The metabolism of carbohydrates, fats and bile pigments by the liver and the alterations in hepatic disease; a review of recent advances.
NAJJAR VA
Pediatrics; 1955 Apr; 15(4):444-66. PubMed ID: 14370877
[No Abstract] [Full Text] [Related]
15. Drug disposition in liver disease.
Fruncillo RJ
Am Fam Physician; 1982 Dec; 26(6):167-9. PubMed ID: 7148640
[No Abstract] [Full Text] [Related]
16. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
[TBL] [Abstract][Full Text] [Related]
17. [Side effects of drugs--predictable hazards for patients with liver disease].
Baumgarten R
Z Arztl Fortbild (Jena); 1983; 77(9):373-5. PubMed ID: 6880279
[No Abstract] [Full Text] [Related]
18. Proteomics in the study of liver pathology.
Parent R; Beretta L
J Hepatol; 2005 Jul; 43(1):177-83. PubMed ID: 15894398
[No Abstract] [Full Text] [Related]
19. [Studies on insulin loading in healthy subjects and liver patients].
Waldhäusl W; Wewalka F
Wien Klin Wochenschr; 1966 Oct; 78(43):734-6. PubMed ID: 5996746
[No Abstract] [Full Text] [Related]
20. [D-thyroxine metabolism in hepatic insufficiency].
Morgner KD; Krüskemper HL; Seifert E
Verh Dtsch Ges Inn Med; 1969; 75():334-6. PubMed ID: 5400143
[No Abstract] [Full Text] [Related]
[Next] [New Search]
